Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-003079-32

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

- To continue to provide chlorambucil to subjects randomized to the chlorambucil arm and aged ≥ 65 and < 81 years of age up to 13 cycles (approximately 12 months), at the discretion of the Investigator - To compare the long term safety of lenalidomide versus chlorambucil in elderly CLL patients


Critère d'inclusion

  • FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA